WO2004037192A3 - Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases - Google Patents

Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases Download PDF

Info

Publication number
WO2004037192A3
WO2004037192A3 PCT/US2003/033524 US0333524W WO2004037192A3 WO 2004037192 A3 WO2004037192 A3 WO 2004037192A3 US 0333524 W US0333524 W US 0333524W WO 2004037192 A3 WO2004037192 A3 WO 2004037192A3
Authority
WO
WIPO (PCT)
Prior art keywords
antimycobacterial
targets
inhibition
identification
treatment
Prior art date
Application number
PCT/US2003/033524
Other languages
French (fr)
Other versions
WO2004037192A2 (en
Inventor
David Howard Avarbock
Harvey Rubin
Andrew Brian Avarbock
Edward Weinstein
Original Assignee
Univ Pennsylvania
David Howard Avarbock
Harvey Rubin
Andrew Brian Avarbock
Edward Weinstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, David Howard Avarbock, Harvey Rubin, Andrew Brian Avarbock, Edward Weinstein filed Critical Univ Pennsylvania
Priority to AU2003285946A priority Critical patent/AU2003285946A1/en
Publication of WO2004037192A2 publication Critical patent/WO2004037192A2/en
Publication of WO2004037192A3 publication Critical patent/WO2004037192A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods for treating mycobacteria infections, especially M. tuberculosis. The present invention also provides inhibitors and methods of using same to treat and detect mycobacteria infections.
PCT/US2003/033524 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases WO2004037192A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003285946A AU2003285946A1 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42013102P 2002-10-22 2002-10-22
US60/420,131 2002-10-22

Publications (2)

Publication Number Publication Date
WO2004037192A2 WO2004037192A2 (en) 2004-05-06
WO2004037192A3 true WO2004037192A3 (en) 2006-09-14

Family

ID=32176517

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/033524 WO2004037192A2 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
PCT/US2003/033692 WO2004037997A2 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033692 WO2004037997A2 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof

Country Status (2)

Country Link
AU (2) AU2003285946A1 (en)
WO (2) WO2004037192A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246349A1 (en) * 2009-04-20 2010-11-03 BKG Pharma ApS Treatment of infectious diseases
MX2012015096A (en) 2010-07-02 2013-05-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators.
NO3175985T3 (en) 2011-07-01 2018-04-28
UY34171A (en) 2011-07-01 2013-01-31 Gilead Sciences Inc FUSIONED HETEROCYCLIC COMPOUNDS AS IONIC CHANNEL MODULATORS
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN103232447B (en) * 2013-04-02 2015-06-03 陕西科技大学 3-acetyl-5-acetylimino-2-(N-phenothiazinyl)-1,3,4-thiadiazole, and preparation method and application thereof
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis
WO2023201199A2 (en) * 2022-04-11 2023-10-19 The Johns Hopkins University Tuberculosis vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834279A (en) * 1996-03-07 1998-11-10 Trustees Of The University Of Pennsylvania Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMARAL L. ET AL.: "Activity of phemathiazines against antibioticOresistant Mycobacterium tuberculosis: A review supporting further studies that mayy elucidate the potential use of thioridazine an anti-tuberculosis therapy", JOURNAL OF ANTIMICROBIAL CHEMPTHERAPY, vol. 47, no. 5, May 2001 (2001-05-01), pages 505 - 511, XP008048568 *
AMARAL L. ET AL.: "Phenothizzines: an alternative to conventional therapy for the initial mangemnt of suspected multidrug resistant tuberculosis", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 14, no. 3, April 2000 (2000-04-01), pages 173 - 176 *
CROWLE A. J. ET AL.: "Chlorpromazine a drug potentially useful for treating mycobacterial infections", CHEMOTHERAPY, vol. 38, no. 6, 1992, pages 410 - 419, XP008048689 *
VIVEIROS M. ET AL.: "Enhancement of antibiotic activity against poly-drug resistant mycobacterium tuberculosis by phenothiazines", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 17, no. 3, May 2001 (2001-05-01), pages 225 - 228 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Also Published As

Publication number Publication date
WO2004037192A2 (en) 2004-05-06
WO2004037997A3 (en) 2004-11-18
WO2004037997A2 (en) 2004-05-06
AU2003294235A8 (en) 2004-05-13
AU2003294235A1 (en) 2004-05-13
AU2003285946A1 (en) 2004-05-13
AU2003285946A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2005115398A3 (en) Hiv integrase inhibitors
WO2005077050A3 (en) Hiv integrase inhibitors
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
WO2004010937A3 (en) Method of treating cancer
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2008133734A3 (en) Method and compositions for treating hiv infections
TW200738700A (en) HIV integrase inhibitors
WO2004037192A3 (en) Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
WO2006078369A3 (en) Methods and compositions for treatment of viral infections
WO2002028434A3 (en) Use of a ppar delta activator for treating inflammatory conditions
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2003004006A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
NO20055518L (en) 5-hydroxyindoles with N-oxide groups, use thereof as phosphodiesterase 4 inhibitor
WO2004032709A3 (en) Inhibition of src for treatment of reperfusion injury related to revascularization
WO2004101512A3 (en) Naphthyridine integrase inhibitors
DE602006014519D1 (en) PEPTIDES FOR TRANSGLUTAMINASE INHIBITION
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
WO2007019101A3 (en) Hiv integrase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP